Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.41
HBIO's Cash-to-Debt is ranked lower than
72% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. HBIO: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
HBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.3  Med: 1.1 Max: No Debt
Current: 0.41
Equity-to-Asset 0.67
HBIO's Equity-to-Asset is ranked higher than
65% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. HBIO: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
HBIO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.75 Max: 0.89
Current: 0.67
0.09
0.89
Piotroski F-Score: 7
Altman Z-Score: 1.25
Beneish M-Score: -2.99
WACC vs ROIC
9.27%
-4.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -2.87
HBIO's Operating Margin % is ranked lower than
63% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. HBIO: -2.87 )
Ranked among companies with meaningful Operating Margin % only.
HBIO' s Operating Margin % Range Over the Past 10 Years
Min: -2.87  Med: 7.38 Max: 11.43
Current: -2.87
-2.87
11.43
Net Margin % -4.12
HBIO's Net Margin % is ranked lower than
63% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. HBIO: -4.12 )
Ranked among companies with meaningful Net Margin % only.
HBIO' s Net Margin % Range Over the Past 10 Years
Min: -17.52  Med: 2.02 Max: 17.58
Current: -4.12
-17.52
17.58
ROE % -5.66
HBIO's ROE % is ranked lower than
66% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.98 vs. HBIO: -5.66 )
Ranked among companies with meaningful ROE % only.
HBIO' s ROE % Range Over the Past 10 Years
Min: -22  Med: 2.38 Max: 22.98
Current: -5.66
-22
22.98
ROA % -3.77
HBIO's ROA % is ranked lower than
62% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. HBIO: -3.77 )
Ranked among companies with meaningful ROA % only.
HBIO' s ROA % Range Over the Past 10 Years
Min: -14.88  Med: 1.78 Max: 16.39
Current: -3.77
-14.88
16.39
ROC (Joel Greenblatt) % -7.09
HBIO's ROC (Joel Greenblatt) % is ranked lower than
64% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.87 vs. HBIO: -7.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HBIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8.13  Med: 23.24 Max: 43.82
Current: -7.09
-8.13
43.82
3-Year Revenue Growth Rate -2.50
HBIO's 3-Year Revenue Growth Rate is ranked lower than
72% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. HBIO: -2.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HBIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -23.7  Med: -0.35 Max: 11.5
Current: -2.5
-23.7
11.5
3-Year EBITDA Growth Rate -31.50
HBIO's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. HBIO: -31.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HBIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.1  Med: -3.8 Max: 29
Current: -31.5
-48.1
29
GuruFocus has detected 1 Warning Sign with Harvard Bioscience Inc $HBIO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HBIO's 10-Y Financials

Financials (Next Earnings Date: 2017-06-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

HBIO Guru Trades in Q1 2016

Chuck Royce 1,546,000 sh (+17.03%)
Jim Simons 557,500 sh (-1.64%)
» More
Q2 2016

HBIO Guru Trades in Q2 2016

Chuck Royce 1,546,000 sh (unchged)
Jim Simons 534,200 sh (-4.18%)
» More
Q3 2016

HBIO Guru Trades in Q3 2016

Chuck Royce 1,661,000 sh (+7.44%)
Jim Simons 508,700 sh (-4.77%)
» More
Q4 2016

HBIO Guru Trades in Q4 2016

Jim Simons 529,200 sh (+4.03%)
Chuck Royce 1,513,600 sh (-8.87%)
» More
» Details

Insider Trades

Latest Guru Trades with HBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334516    SIC: 3826
Compare:NAS:BIOL, OTCPK:TDMMF, NAS:EKSO, AMEX:BVX, NAS:LAKE, NAS:LENS, AMEX:INFU, OTCPK:TSNLF, AMEX:MLSS, NAS:CASM, NAS:IVTY, AMEX:RVP, AMEX:ISR, AMEX:TRXC, AMEX:DXR, NAS:BLFS, NAS:SIEN, NAS:ATEC, OTCPK:LDSYF, NAS:PDEX » details
Traded in other countries:HBI.Germany,
Harvard Bioscience Inc is a developer, manufacturer and marketer of scientific instruments, systems and lab consumables used to advance life science for basic research, drug discovery, clinical and environmental testing.

Harvard Bioscience Inc is a Delaware corporation, which began its business in 1901. The Company developer, manufacturer and marketer of scientific instruments, systems and lab consumables used to advance life science for basic research, drug discovery, clinical and environmental testing. It has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada, and China. The Company sells its products to researchers in over 100 countries through its sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. The Company core product range is organized into five product families: Fluidics, Lab Equipment and Supplies, Molecular Analysis, Cell Physiology, and Animal Physiology. It primarily sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI, and CMA Microdialysis. The Fluidics product family includes Company's traditional syringe pump and peristaltic pump product lines. The products are used in many life science and industrial applications that require accurately controlled fluid dispensing, including infusion, perfusion, cellular microinjection, microfluidics, mass spectrometry calibration, electrospinning and microdialysis. The primary brands are Harvard Apparatus, Harvard Pumps, and KD Scientific. The Lab Equipment and Supplies product family includes products for molecular biology labs with a liquid handling focus. It consists of pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables. Its brands include Denville Scientific, AHN, and others. The Molecular Analysis product family includes spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments. The Company sells spectrophotometers under the names Libra, WPA and BioDrop. The Cell Physiology product family consists of electrophysiology products. The Animal Physiology product family includes instruments and accessories for tissue, organ and animal based lab research, including surgical products, infusion systems, microdialysis instruments, behavior research systems, isolated organ and tissue bath systems, bioreactors for regenerative medicine research, and in vivo electrophysiology recording and stimulation systems. Its product offerings are marketed through Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS and TBSI brands and entities. The Company competes with several companies that provides instruments for life science research including, Lonza Group Ltd., Becton Dickinson

Ratios

vs
industry
vs
history
Forward PE Ratio 17.18
HBIO's Forward PE Ratio is ranked higher than
92% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.75 vs. HBIO: 17.18 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.31
HBIO's PB Ratio is ranked higher than
82% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. HBIO: 1.31 )
Ranked among companies with meaningful PB Ratio only.
HBIO' s PB Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.25 Max: 2.41
Current: 1.31
0.62
2.41
PS Ratio 0.89
HBIO's PS Ratio is ranked higher than
85% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. HBIO: 0.89 )
Ranked among companies with meaningful PS Ratio only.
HBIO' s PS Ratio Range Over the Past 10 Years
Min: 0.51  Med: 1.08 Max: 2.01
Current: 0.89
0.51
2.01
Price-to-Free-Cash-Flow 23.93
HBIO's Price-to-Free-Cash-Flow is ranked higher than
70% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.12 vs. HBIO: 23.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HBIO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.94  Med: 15.85 Max: 6590
Current: 23.93
4.94
6590
Price-to-Operating-Cash-Flow 17.52
HBIO's Price-to-Operating-Cash-Flow is ranked higher than
56% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.55 vs. HBIO: 17.52 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HBIO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.6  Med: 13.75 Max: 647.14
Current: 17.52
4.6
647.14
EV-to-EBITDA 56.79
HBIO's EV-to-EBITDA is ranked lower than
91% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.75 vs. HBIO: 56.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
HBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.1  Med: 8.7 Max: 75.9
Current: 56.79
3.1
75.9
Shiller PE Ratio 46.29
HBIO's Shiller PE Ratio is ranked higher than
50% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.77 vs. HBIO: 46.29 )
Ranked among companies with meaningful Shiller PE Ratio only.
HBIO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.07  Med: 52.6 Max: 439
Current: 46.29
3.07
439
Current Ratio 3.11
HBIO's Current Ratio is ranked higher than
68% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. HBIO: 3.11 )
Ranked among companies with meaningful Current Ratio only.
HBIO' s Current Ratio Range Over the Past 10 Years
Min: 1.5  Med: 3.73 Max: 7.37
Current: 3.11
1.5
7.37
Quick Ratio 1.75
HBIO's Quick Ratio is ranked higher than
55% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. HBIO: 1.75 )
Ranked among companies with meaningful Quick Ratio only.
HBIO' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 2.78 Max: 6.78
Current: 1.75
1.12
6.78
Days Inventory 140.46
HBIO's Days Inventory is ranked lower than
59% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. HBIO: 140.46 )
Ranked among companies with meaningful Days Inventory only.
HBIO' s Days Inventory Range Over the Past 10 Years
Min: 97.89  Med: 108.84 Max: 140.46
Current: 140.46
97.89
140.46
Days Sales Outstanding 54.99
HBIO's Days Sales Outstanding is ranked higher than
61% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.07 vs. HBIO: 54.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
HBIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.14  Med: 54.61 Max: 64.58
Current: 54.99
47.14
64.58
Days Payable 40.31
HBIO's Days Payable is ranked lower than
60% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.88 vs. HBIO: 40.31 )
Ranked among companies with meaningful Days Payable only.
HBIO' s Days Payable Range Over the Past 10 Years
Min: 29.04  Med: 37.92 Max: 53.48
Current: 40.31
29.04
53.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.80
HBIO's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. HBIO: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HBIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -75  Med: -1.65 Max: 2.8
Current: -2.8
-75
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 9.48
HBIO's Price-to-Net-Current-Asset-Value is ranked lower than
61% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.51 vs. HBIO: 9.48 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HBIO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.14  Med: 4.13 Max: 14.46
Current: 9.48
2.14
14.46
Price-to-Tangible-Book 6.11
HBIO's Price-to-Tangible-Book is ranked lower than
57% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.31 vs. HBIO: 6.11 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HBIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.88  Med: 3.19 Max: 7.78
Current: 6.11
1.88
7.78
Price-to-Intrinsic-Value-Projected-FCF 1.09
HBIO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
88% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. HBIO: 1.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HBIO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.49  Med: 1.01 Max: 1.31
Current: 1.09
0.49
1.31
Price-to-Median-PS-Value 0.83
HBIO's Price-to-Median-PS-Value is ranked higher than
74% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. HBIO: 0.83 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HBIO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.21 Max: 4.43
Current: 0.83
0.67
4.43
Earnings Yield (Greenblatt) % -2.36
HBIO's Earnings Yield (Greenblatt) % is ranked lower than
70% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. HBIO: -2.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HBIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.48  Med: 8.2 Max: 22.5
Current: -2.36
-2.48
22.5
Forward Rate of Return (Yacktman) % -29.62
HBIO's Forward Rate of Return (Yacktman) % is ranked lower than
99% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.56 vs. HBIO: -29.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HBIO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -30.2  Med: 7.2 Max: 18.4
Current: -29.62
-30.2
18.4

More Statistics

Revenue (TTM) (Mil) $104.5
EPS (TTM) $ -0.13
Beta0.82
Short Percentage of Float0.70%
52-Week Range $2.25 - 3.90
Shares Outstanding (Mil)34.58

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 100 105
EPS ($) 0.16 0.22
EPS without NRI ($) 0.16 0.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for HBIO

Headlines

Articles On GuruFocus.com
Latest Stock Trades from Century Management: Buys POT, HWCC, PICO, AU, KGC Jan 15 2014 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 05 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Harvard Bioscience Inc, BGC Partners Inc., Chatham Lodg Sep 25 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Spartech Corp, Harvard Bioscience Inc, Rural/Metro Corp Sep 18 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 09 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Aug 10 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q/A) Feb 19 2009 

More From Other Websites
HARVARD BIOSCIENCE INC Financials Mar 23 2017
Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017 Mar 21 2017
HARVARD BIOSCIENCE INC Files SEC form 10-K, Annual Report Mar 17 2017
Edited Transcript of HBIO earnings conference call or presentation 9-Mar-17 9:30pm GMT Mar 10 2017
Harvard Bioscience reports 4Q loss Mar 09 2017
Harvard Bioscience reports 4Q loss Mar 09 2017
Harvard Bioscience Inc Earnings Call scheduled for 4:30 pm ET today Mar 09 2017
HARVARD BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 09 2017
Harvard Bioscience Reports Fourth Quarter and Year-End 2016 Results and 2017 Financial Guidance Mar 09 2017
Q4 2016 Harvard Bioscience Inc Earnings Release - After Market Close Mar 09 2017
Harvard Bioscience Schedules Fourth Quarter 2016 Conference Call for March 9 at 4:30 PM ET Feb 23 2017
ETFs with exposure to Harvard Bioscience, Inc. : January 12, 2017 Jan 12 2017
Harvard Bioscience an 'Asymmetrical Long Shot' Dec 19 2016
ETFs with exposure to Harvard Bioscience, Inc. : December 16, 2016 Dec 16 2016
Harvard Bioscience, Inc. (HBIO): Are Hedge Funds Right About This Stock? Dec 16 2016
HARVARD BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report Nov 03 2016
ETF’s with exposure to Harvard Bioscience, Inc. : November 2, 2016 Nov 02 2016
Harvard Bioscience, Inc. :HBIO-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016 Oct 31 2016
Edited Transcript of HBIO earnings conference call or presentation 27-Oct-16 8:30pm GMT Oct 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)